SCHEMBL23326784

SCHEMBL23326784

CON(C)C(=O)c1cc(C(F)(F)F)cc(NC(C)=O)c1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN5 P54829 1/20 0.44
CYP1A2 P05177 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
GPR35 Q9HC97 3/20 0.41
RXFP1 Q9HBX9 2/20 0.38
MLYCD O95822 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
ATM Q13315 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TSHR P16473 1/20 0.35
POLB P06746 1/20 0.34
NOTUM Q6P988 1/20 0.34
MPO P05164 1/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
MAPT P10636 1/20 0.33
CFTR P13569 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29861148 1.00 PTPN5 (0.44) PTPN5CYP1A2CYP2C9CYP2C19GPR35
SCHEMBL23326539 0.82 PTPN5 (0.51) PTPN5CYP1A2CYP2C9CYP2C19GPR35
SCHEMBL25406281 0.81 MLYCD (0.41) GPR35MLYCDNOTUMCFTRP2RX1
SCHEMBL23326510 0.80 PTPN5 (0.50) PTPN5CYP1A2CYP2C9CYP2C19GPR35
SCHEMBL29861499 0.80 PTPN5 (0.50) PTPN5CYP1A2CYP2C9CYP2C19GPR35
SCHEMBL28668894 0.78 MLYCD (0.40) PTPN5CYP1A2CYP2C9CYP2C19MLYCD
SCHEMBL31643114 0.78 MLYCD (0.40) PTPN5CYP1A2CYP2C9CYP2C19MLYCD
SCHEMBL28655727 0.75 MLYCD (0.45) GPR35MLYCDPOLBNOTUMMAPT
SCHEMBL23326683 0.73 ADORA3 (0.44) PTPN5CYP1A2CYP2C9CYP2C19GPR35
SCHEMBL29861524 0.73 ADORA3 (0.44) PTPN5CYP1A2CYP2C9CYP2C19GPR35

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4620531-A2 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. (US) 2025-09-24 EP disclosed
US-12258366-B2 Bicyclic heteroaryl compounds and uses thereof Revolution Medicines, Inc. (US) 2025-03-25 US disclosed
US-20230365605-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-11-16 US disclosed
US-20230365605-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-11-16 US disclosed
CN-116425742-A Bicyclic heteroaryl compounds and uses thereof 锐新医药公司 2023-07-14 CN disclosed
CN-114901662-A Bicyclic heteroaryl compounds and uses thereof 锐新医药公司 2022-08-12 CN disclosed
US-11168102-B1 Bicyclic heteroaryl compounds and uses thereof Revolution Medicines, Inc. (US) 2021-11-09 US disclosed
US-11168102-B1 Bicyclic heteroaryl compounds and uses thereof Revolution Medicines, Inc. (US) 2021-11-09 US disclosed
US-20210139517-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. 2021-05-13 US disclosed
US-20210139517-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. 2021-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11168102-B1 Bicyclic heteroaryl compounds and uses thereof SOS1, SOST, SOS2 PTPN5 442/4885CYP1A2 1997/4885CYP2C9 2750/4885
US-20230365605-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF SOST, SOS1, SOS2 PTPN5 883/4885CYP1A2 2086/4885CYP2C9 3034/4885
US-20210139517-A1 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF SOST, SOS1, SOS2 PTPN5 883/4885CYP1A2 2086/4885CYP2C9 3034/4885
US-12258366-B2 Bicyclic heteroaryl compounds and uses thereof SOST, SOS1, SOS2 PTPN5 883/4885CYP1A2 2086/4885CYP2C9 3034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.